Case and Research Letter
Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience
Los inhibidores selectivos de la IL23 son en su mayoría efectivos y seguros en pacientes con psoriasis y fallo previo a tratamientos biológicos anti IL-17. Una experiencia de práctica clínica real a 52 semanas
J. Arroyo-Andrés
, D. Falkenhain-López, M. Agud-Dios, R. Rivera-Díaz
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
Leído
5507
Vecesse ha leído el artículo
1665
Total PDF
3842
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 10 | 123 | 77 | 200 |
| 2025 9 | 119 | 53 | 172 |
| 2025 8 | 81 | 51 | 132 |
| 2025 7 | 116 | 33 | 149 |
| 2025 6 | 162 | 28 | 190 |
| 2025 5 | 185 | 49 | 234 |
| 2025 4 | 180 | 33 | 213 |
| 2025 3 | 154 | 28 | 182 |
| 2025 2 | 134 | 36 | 170 |
| 2025 1 | 121 | 46 | 167 |
| 2024 12 | 113 | 48 | 161 |
| 2024 11 | 135 | 70 | 205 |
| 2024 10 | 138 | 57 | 195 |
| 2024 9 | 105 | 32 | 137 |
| 2024 8 | 130 | 66 | 196 |
| 2024 7 | 116 | 42 | 158 |
| 2024 6 | 118 | 43 | 161 |
| 2024 5 | 117 | 47 | 164 |
| 2024 4 | 104 | 40 | 144 |
| 2024 3 | 101 | 51 | 152 |
| 2024 2 | 102 | 39 | 141 |
| 2024 1 | 79 | 46 | 125 |
| 2023 12 | 83 | 38 | 121 |
| 2023 11 | 86 | 39 | 125 |
| 2023 10 | 116 | 49 | 165 |
| 2023 9 | 84 | 43 | 127 |
| 2023 8 | 65 | 16 | 81 |
| 2023 7 | 104 | 40 | 144 |
| 2023 6 | 88 | 35 | 123 |
| 2023 5 | 97 | 34 | 131 |
| 2023 4 | 113 | 48 | 161 |
| 2023 3 | 62 | 52 | 114 |
| 2023 2 | 94 | 58 | 152 |
| 2022 1 | 102 | 96 | 198 |
| 2022 12 | 15 | 102 | 117 |
Mostrar todo
